[Loxapine succinate: a new neuroleptic].
Commercialized in the U.S.A. a few years ago, the loxapine succinate appears to be interesting among neuroleptic compounds. Used in 28 chronic schizophrenics, 19 of which were neuroleptic resistent patients, the parenteral route proved to be anti-psychotic and sedative in 26 patients. The usual daily dosages were between 100 and 200 mg. The local and general tolerances were good. The side effects were mild and essentially vegetative. The therapeutic efficiency seems to be better at the same dosages with the oral form than with the parenteral form.
D000328:Adult; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D010054:Brief Psychiatric Rating Scale; D002908:Chronic Disease; D003989:Dibenzoxazepines / Q000627:therapeutic use*; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008152:Loxapine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D012893:Sleep Wake Disorders / Q000139:chemically induced; D013997:Time Factors
D003989:Dibenzoxazepines; D008152:Loxapine
Le succinate de loxapine: un nouveau neuroleptique.